Table 3.
Ongoing Fe-based stents trials in cardiovascular application.
| Trial | Stent | Condition | Study type | Scaffold material | Surface modification | Eluting | n | Expected duration | Last update | Primary endpoint |
|---|---|---|---|---|---|---|---|---|---|---|
| IRONMANN-II | IBS | Stable Coronary artery disease | Prospective, Multicenter, Randomized, Single Blinded Trial | Iron | – | Sirolimus-Eluting | 518 | 24 months | December 2022 | Scaffold late lumen loss at 12 month |
| GENIUS | IBS | Infrapopliteal Arterial Stenosis | Prospective, Non-randomized, Non-comparative study | Iron | – | Sirolimus-Eluting | 120 | 1 year | March 2022 | Primary Patency Rate (180 days) |
| IRONMANN-III | IBS | Stable Coronary artery disease | Prospective, Multicentr, Randomized, Single Blinded Trial | Iron | – | Sirolimus-Elu ting | 1096 | 24 months | March 2022 | Target Lesion Failure at 1 year |
| IRIS | IBS | Pulmonary Artery Stenosis | Prospective, single group | Nitrited Iron | – | Sirolimus-Eluting | 82 | 24 Months | November 2021 | Rate of freedom from in-stent restenosis |
| A First-in Man Study to Evaluate the Feasability and Safety of IBS | IBS | Stable Coronary artery disease | Prospective, Non-randomized, Non-comparative study | Iron | – | Sirolimus-Elu ting | 15 | 1 year | August 2018 | Target Lesion Failure at 1 month |